- Home
- MAIA vs CNTB Comparison
MAIA vs CNTB Comparison
Compare MAIA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- CNTB
- Stock Information
- Founded
- MAIA 2018
- CNTB 2012
- Country
- MAIA United States
- CNTB United States
- Employees
- MAIA N/A
- CNTB N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- CNTB Health Care
- Exchange
- MAIA Nasdaq
- CNTB Nasdaq
- Market Cap
- MAIA 46.7M
- CNTB 43.2M
- IPO Year
- MAIA 2022
- CNTB 2021
- Fundamental
- Price
- MAIA $2.03
- CNTB $0.81
- Analyst Decision
- MAIA
- CNTB Strong Buy
- Analyst Count
- MAIA 0
- CNTB 1
- Target Price
- MAIA N/A
- CNTB $8.00
- AVG Volume (30 Days)
- MAIA 319.8K
- CNTB 218.6K
- Earning Date
- MAIA 05-20-2025
- CNTB 03-31-2025
- Dividend Yield
- MAIA N/A
- CNTB N/A
- EPS Growth
- MAIA N/A
- CNTB N/A
- EPS
- MAIA N/A
- CNTB N/A
- Revenue
- MAIA N/A
- CNTB $26,033,000.00
- Revenue This Year
- MAIA N/A
- CNTB N/A
- Revenue Next Year
- MAIA N/A
- CNTB N/A
- P/E Ratio
- MAIA N/A
- CNTB N/A
- Revenue Growth
- MAIA N/A
- CNTB N/A
- 52 Week Low
- MAIA $1.40
- CNTB $0.51
- 52 Week High
- MAIA $5.99
- CNTB $2.08
- Technical
- Relative Strength Index (RSI)
- MAIA 53.91
- CNTB 56.38
- Support Level
- MAIA $1.80
- CNTB $0.78
- Resistance Level
- MAIA $2.18
- CNTB $0.85
- Average True Range (ATR)
- MAIA 0.30
- CNTB 0.06
- MACD
- MAIA -0.01
- CNTB 0.01
- Stochastic Oscillator
- MAIA 30.29
- CNTB 82.40
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.